Single Center Experience Study with Pembrolizumab in Patients with BRAF Mutant Negative Metastatic Melanoma
The aim of the paper was to determine the efficacy, toxicity and progression free survival with anti-PD-1 immunotherapy pembrolizumab in BRAF wild type metastatic melanoma patients with good performance status (ECOG PS 0-1). From February 2017 to April 2018, 17 patients with BRAF mutant wild type me...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2018-12-01
|
| Series: | Acta Facultatis Medicae Naissensis |
| Subjects: | |
| Online Access: | http://www.degruyter.com/view/j/afmnai.2018.35.issue-4/afmnai-2018-0028/afmnai-2018-0028.xml?format=INT |